PDGFRB and lung adenocarcinoma: A blockage of PDGFR signalling has been shown to suppress angiogenesis and tumour growth and a case in point is Dasatinib, a PDGFR inhibitor, which can partially reverse the pro-tumorigenic effect of CAFs in lung adenocarcinoma and may be a potential treatment strategy [67].